Related Experiment Videos
Bezafibrate induced rhabdomyolysis
E Kanterewicz1, R Sanmartí, J Riba
1Servei de Medicina Interna (Reumatologia), Hospital General de Vic, Barcelona, Spain.
Annals of the Rheumatic Diseases
|April 1, 1992
Summary
A 70-year-old woman developed rhabdomyolysis while taking bezafibrate for hypercholesterolemia. Discontinuation of bezafibrate led to symptom resolution, highlighting a potential drug-induced risk.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- A 70-year-old female patient with hypercholesterolemia and hypertension was admitted for angina pectoris.
- She was on verapamil, nifedipine, aspirin, and bezafibrate (400 mg BID) for 40 days prior to admission.
Observation:
- The patient developed podagra 24 hours after admission, treated with indomethacin.
- Myocardial infarction was suspected 8 days post-admission, followed by symptoms of rhabdomyolysis the next day.
Findings:
- Laboratory tests confirmed rhabdomyolysis.
- Symptoms resolved within seven days after bezafibrate was discontinued.
Implications:
- Bezafibrate can induce rhabdomyolysis, particularly in patients with compromised renal function.
- Clinicians should monitor for this adverse effect in patients treated with bezafibrate.
- This case underscores the importance of considering drug-induced myotoxicity in patients presenting with unexplained muscle symptoms.